Medimmune Limited

Astrazeneca Ab

Steven Godfrey Lane

Philip Mallinder

Simon Charles Cruwys

Ralph Raymond Minter

Claire Louise Dobson

Philip Newton

Maria Anastasia Theresa Groves

Ann-Charlott Steffen

Keith Bowers

Isabelle Veronique Yolande Ossona De Mendez

Martin Schwickart

Robert George Edward Holgate

The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.

Anti-IL-18 antibodies and their uses

Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumors associated with IL-6.

Compounds

The present invention relates to a method of mutagenesis for introducing mutations into a molecule and, in particular, to methods that may be applied to populations of molecules for the generation or screening of libraries involving the mutation of multiple molecules.

Method of mutagenesis

Anti-human IL-6 antibodies

Binding members, especially antibody molecules that bind the IL-6:IL-6Ra complex formed by IL-6 and IL-6Ra, and do not bind either IL-6 or IL-6Ra alone. The binding members may have greater specificity for inhibiting pathological effects of IL-6 rather than beneficial effects of IL-6, as compared with binding members that bind IL-6 or IL-6Ra outside the IL-6:IL-6Ra complex.

Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor

Growing community of inventors

London, United Kingdom

Steven Godfrey Lane